TY - JOUR
T1 - Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells
AU - Cho, Seung Woo
AU - Goldberg, Michael
AU - Son, Sun Mi
AU - Xu, Qiaobing
AU - Yang, Fan
AU - Mei, Ying
AU - Bogatyrev, Said
AU - Langer, Robert
AU - Anderson, Daniel G.
PY - 2009/10/9
Y1 - 2009/10/9
N2 - Here, nanoparticles composed of lipid-like materials (lipidoids) to facilitate non-viral delivery of small interfering RNA (siRNA) to endothelial cells (ECs) are developed. Nanoparticles composed of siRNA and lipidoids with small size (∼200 nm) and positive charge (∼34 mV) are formed by self-assembly of lipidoids and siRNA. Ten lipidoids are synthesized and screened for their ability to facilitate the delivery of siRNA into ECs. Particles composed of leading lipidoids show significantly better delivery to ECs than a leading commercially available transfection reagent, Lipofectamine 2000. As a model of potential therapeutic application, nanoparticles composed of the top performing lipidoid, NA114, are studied for their ability to deliver siRNA targeting anti-angiogenic factor (SHP-1) to human ECs. Silencing of SHP-1 expression significantly enhances EC proliferation and decreases EC apoptosis under a simulated ischemic condition.
AB - Here, nanoparticles composed of lipid-like materials (lipidoids) to facilitate non-viral delivery of small interfering RNA (siRNA) to endothelial cells (ECs) are developed. Nanoparticles composed of siRNA and lipidoids with small size (∼200 nm) and positive charge (∼34 mV) are formed by self-assembly of lipidoids and siRNA. Ten lipidoids are synthesized and screened for their ability to facilitate the delivery of siRNA into ECs. Particles composed of leading lipidoids show significantly better delivery to ECs than a leading commercially available transfection reagent, Lipofectamine 2000. As a model of potential therapeutic application, nanoparticles composed of the top performing lipidoid, NA114, are studied for their ability to deliver siRNA targeting anti-angiogenic factor (SHP-1) to human ECs. Silencing of SHP-1 expression significantly enhances EC proliferation and decreases EC apoptosis under a simulated ischemic condition.
UR - http://www.scopus.com/inward/record.url?scp=70349687233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349687233&partnerID=8YFLogxK
U2 - 10.1002/adfm.200900519
DO - 10.1002/adfm.200900519
M3 - Article
AN - SCOPUS:70349687233
SN - 1616-301X
VL - 19
SP - 3112
EP - 3118
JO - Advanced Functional Materials
JF - Advanced Functional Materials
IS - 19
ER -